Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thienopyridines and aspirin. Although effective, these drugs carry risks of increased bleeding and drug 'resistance', underpinning a drive for new antiplatelet agents. To discover such drugs, one strategy is to identify a suitable druggable target and then find small molecules that modulate it. A good and unexploited target is the platelet collagen receptor, GPVI, which promotes thrombus formation. To identify inhibitors of GPVI that are safe and bioavailable, we docked a FDA-approved drug library into the GPVI collagen-binding site in silico. We now report that losartan and cinanserin inhibit GPVI-mediated platelet activation in a selective, competitive and dose-dependent manner. This mechanism of action likely underpins the cardioprotective effects of losartan that could not be ascribed to its antihypertensive effects. We have, therefore, identified small molecule inhibitors of GPVI-mediated platelet activation, and also demonstrated the utility of structure-based repurposing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074120 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101209 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Structure-based drug design; Computational strategies in drug discovery; Antihypertensive agents; Antiviral drugs; Molecular docking; QSAR; Pharmacological insights.
Comput Biol Chem
August 2025
Department of Green Chemistry, National Research Centre, Dokki, P.O. Box 12622, Cairo, Egypt. Electronic address:
This review meticulously examines the development, design, and pharmacological assessment of both well known antiviral and antihypertensive medications all time employing new chemical techniques and structure-based drug design to design and synthesize vital therapeutic entities such as aliskiren (renin inhibitor), captopril (a2-ACE-Inhibitor), dorzolamide (inhibitor of carbonic anhydrase) the review demonstrates initial steps regarding the significance of stereoselective synthesis, metal chelating pharmacophores, and rational molecular properties. More importantly, protease inhibitors (i.e.
View Article and Find Full Text PDFDiscovery of Small-Molecule PD-L1 Inhibitors via Virtual Screening and Their Immune-Mediated Anti-Tumor Effects.
Pharmaceuticals (Basel)
August 2025
School of Pharmacy, Jiangsu University, 301 Xuefu Road, Zhenjiang 212013, China.
: Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have achieved clinical success but face drawbacks such as poor oral bioavailability, limited tumor penetration, and immune-related adverse events. Small-molecule inhibitors present a promising alternative that may overcome these challenges. : Here, an integrated computational framework combining ligand-based pharmacophore modeling and structure-based molecular docking was utilized to screen a comprehensive library consisting of traditional Chinese medicine-derived compounds and clinically approved drugs.
View Article and Find Full Text PDFInhibiting viral entry of bat-derived coronavirus HKU5-CoV-2: Targeting spike protein S1 subunit with FDA-approved antivirals-A structural dynamics and energetics study.
Bioorg Chem
August 2025
Computational Chemistry and Drug Discovery Division, Quanta Calculus, Greater Noida 201310, Uttar Pradesh, India.
The ongoing risk of zoonotic transmission from bat-derived coronaviruses underscores the urgent need for broad-spectrum antiviral strategies. In this study, we investigate the potential of Food and Drug Administration (FDA)-approved antiviral drugs to inhibit the S1 C-terminal domain of the spike protein from HKU5-CoV-2, a Merbecovirus closely related to Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A structure-based virtual screening approach was employed, followed by 3000 ns molecular dynamics (MD) simulations and binding free energy estimation using MM-PBSA analysis.
View Article and Find Full Text PDFComputational discovery and repurposing of chloramphenicol succinate as a potent P2Y receptor antagonist for inflammatory bowel disease therapy.
J Adv Res
August 2025
College of Pharmaceutical Sciences, Jiangsu Key Laboratory of Neuropsychiatric Diseases and Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China. Electronic address:
Introduction: The P2Y receptor (P2YR), a Gi-coupled receptor activated by UDP-glucose, plays a critical role in inflammatory responses and immune regulation. Existing P2YR antagonists face limitations such as poor bioavailability and structural homogeneity, hindering therapeutic development for inflammatory bowel disease (IBD). Drug repurposing offers a promising strategy to bypass traditional drug discovery challenges by leveraging approved drugs with established safety profiles.
View Article and Find Full Text PDFSupport vector machine classification-guided identification of novel monoamine oxidase-B inhibitors via structure-based modeling to treat neurodegenerative diseases.
Int J Biol Macromol
September 2025
Dongguan Key Laboratory of Computer-Aided Drug Design, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan 523710, China; Guangdong Medical University Key Laboratory of Big Data Mining and Precision Drug Design, Guangdong Provincial Key Laboratory for Research and Developm
Monoamine oxidase-B (MAO-B) is a mitochondrial enzyme that catalyzes the oxidative deamination of dopamine and other neurotransmitters, contributing to neurodegeneration via increased oxidative stress. Elevated MAO-B activity is implicated in neurodegenerative disorders such as Parkinson's and Alzheimer's diseases. Although several MAO-B inhibitors are clinically available, their therapeutic utility is often limited by poor selectivity, off-target effects, and suboptimal pharmacokinetics.
View Article and Find Full Text PDF